What is Zacks Research’s Forecast for Azitra Q3 Earnings?

Azitra, Inc. (NYSEAMERICAN:AZTR) – Research analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for Azitra in a report issued on Monday, November 2nd. Zacks Research analyst J. Vandermosten now expects that the company will earn ($0.25) per share for the quarter, down from their prior forecast of ($0.20). The consensus estimate for Azitra’s current full-year earnings is ($2.05) per share. Zacks Research also issued estimates for Azitra’s Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($2.05) EPS, FY2027 earnings at ($0.64) EPS and FY2028 earnings at ($0.61) EPS.

Azitra Stock Performance

Shares of Azitra stock opened at $0.60 on Monday. The company has a fifty day simple moving average of $1.77 and a 200-day simple moving average of $1.88. Azitra has a 12-month low of $0.52 and a 12-month high of $4.30.

Azitra (NYSEAMERICAN:AZTR) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.55).

Azitra Company Profile

Azitra, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapies for dermatological conditions. The company combines microbiology, genetic engineering and computational tools to identify and develop targeted treatments intended to address diseases affecting the skin. Azitra’s platform centers on engineered strains of beneficial skin bacteria and biologic compounds designed to deliver therapeutic proteins or otherwise influence the skin’s local environment. Its development programs have focused on conditions including inflammatory skin disorders, rare genetic diseases and treatment-related dermatologic complications.